5 days ago
- Health
- Wall Street Journal
Novartis's Ianalumab Meets Key Goal in Late-Stage Trials for Autoimmune Disease
Novartis NOVN 1.09%increase; green up pointing triangle said its ianalumab drug candidate met the primary goal in two late-stage trials evaluating its efficacy for treating autoimmune disorder Sjoegren's disease.
The Swiss pharmaceutical company said Monday that the drug achieved the main goal of the phase 3 trials by showing statistically significant improvements in disease activity.
